Should atrial fibrillation patients with hypertension as an additional risk factor of the CHA2DS2-VASc score receive oral anticoagulation？  

作　　者：Juan WANG Da-Peng ZHANG Hong-Bin LIU Jiu-Chang ZHONG Xin-Chun YANG 

机构地区：[1]Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China [2]Department of Cardiology, People's Liberation Army General Hospital, Beijing, China

出　　处：《Journal of Geriatric Cardiology》2018年第3期229-234,共6页老年心脏病学杂志（英文版）

摘　　要：Hypertension has been found to be increased a risk of stroke in atrial fibrillation （AF）. Both the European and U.S. guidelines advocate the use of the CHA2DSz-VASc （congestive heart failure, hypertension, age 〉 75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65-74 years, sex category） scheme for risk stratification. Although vitamin K antagonists is more effective than acetyl-salicylic acid at preventing ischaemic stroke, its benefit is offs by an increased haemorrhage risk. The risk of ischemic stroke in patients with AF and a CHA2DS2-VASc score of 1 are considered to be low risk and may be not expected to benefit from anticoagulation therapy. Hyper-tension carries an increased risk of ischemic stroke, however, it is also a clear risk factor for hemorrhage in AF. Therefore, the optimal anti-thrombotic management is highlighted in patients with AF with only one risk factor especially hypertension.

关 键 词：Atrial fibrillation HYPERTENSION Stroke 

分 类 号：TS218[轻工技术与工程—粮食、油脂及植物蛋白工程] TS214.2[轻工技术与工程—食品科学与工程]